Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539008 | 0.79 | KDM4E (0.53) | KDM4ETYRO3DYRK1B | |
| SCHEMBL3963582 | 0.76 | KDM4E (0.50) | KDM4ETYRO3DYRK1B | |
| SCHEMBL15718879 | 0.76 | KDM4E (0.50) | KDM4ETYRO3DYRK1B | |
| SCHEMBL2934833 | 0.76 | ALDH1A1 (0.50) | ADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL1551962 | 0.76 | KDM4E (0.50) | KDM4ETYRO3DYRK1BSMN1; SMN2 | |
| SCHEMBL15571871 | 0.72 | KDM4E (0.46) | KDM4ETYRO3DYRK1BSMN1; SMN2 | |
| SCHEMBL15570735 | 0.69 | KDM4E (0.43) | KDM4ETYRO3DYRK1B | |
| SCHEMBL357005 | 0.67 | KDM4E (1.00) | KDM4ETYRO3DYRK1BSMN1; SMN2 | |
| SCHEMBL4672152 | 0.65 | KDM4E (0.52) | KDM4ETYRO3DYRK1B | |
| Hydrochloric Acid SCHEMBL4982885 | 0.65 | KDM4E (0.96) | KDM4ETYRO3DYRK1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103003279-B | Purine compounds selective for PI3K P110 and methods of use thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-23 | — | — | CN | disclosed |
| EP-2593455-B1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-03-18 | — | — | EP | disclosed |
| EP-2593455-A1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| CN-103003279-A | Purine compounds selective for PI3K P110 delta and methods of use thereof | HOFFMANN LA ROCHE | 2013-03-27 | — | — | CN | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007493-A1 | PURINE COMPOUNDS SELECTIVE FOR ΡI3Κ P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | KDM4E 3949/4885TYRO3 666/4885DYRK1B 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.